• What's New
  • News Releases
  • Apr. 26, 2018 (PDF/111KB)Finances
    Sumitomo Dainippon Pharma Revises Financial Forecasts (J-GAAP) and Announces Financial Forecasts under IFRS
  • Apr. 25, 2018 (PDF/108KB)R&D
    Sumitomo Dainippon Pharma Announces Joint Research Agreement with MMV for Identification of Antimalarial Candidate Compounds
  • Apr. 18, 2018 (PDF/101KB)Corporate
    Sumitomo Dainippon Pharma Announces U.S. Appellate Court Decision on Substance Patent Infringement Lawsuit Regarding LATUDA
  • Apr. 04, 2018 (PDF/323KB)Products
    Sunovion Announces Lonhala Magnair (glycopyrrolate) Inhalation Solution Now Available in the U.S. for the Treatment of COPD
  • Apr. 03, 2018R&D
    Posted Disclosure of Clinical Study Data
  • Apr. 26, 2018 (PDF/111KB)Finances
    Sumitomo Dainippon Pharma Revises Financial Forecasts (J-GAAP) and Announces Financial Forecasts under IFRS
  • Apr. 25, 2018 (PDF/108KB)R&D
    Sumitomo Dainippon Pharma Announces Joint Research Agreement with MMV for Identification of Antimalarial Candidate Compounds
  • Apr. 18, 2018 (PDF/101KB)Corporate
    Sumitomo Dainippon Pharma Announces U.S. Appellate Court Decision on Substance Patent Infringement Lawsuit Regarding LATUDA
  • Apr. 04, 2018 (PDF/323KB)Products
    Sunovion Announces Lonhala Magnair (glycopyrrolate) Inhalation Solution Now Available in the U.S. for the Treatment of COPD
  • Apr. 02, 2018 (PDF/387KB)R&D
    Sunovion Submits New Drug Application to the FDA for Apomorphine Sublingual Film (APL-130277) for the Treatment of OFF Episodes Associated with Parkinson's Disease

more